Search results for "Lupus erythematosus"

showing 10 items of 140 documents

Systemic lupus erythematosus and bullous pemphigoid with dramatic response to dapsone

2017

Patient: Female, 11 Final Diagnosis: Bullous pemphigoid in systemic lupus erythematosus Symptoms: Bullous lupus • photosensitive rash • synovitis Medication:— Clinical Procedure: Pharmacological treatment Specialty: Rheumatology Objective: Unusual clinical course Background: Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs. Case Report: We describe the clinical case of an 11-year-old girl with SLE. She showed bullous skin les…

Pemphigoidmedicine.medical_specialtyAntimalarials; Child; Dapsone; Female; Humans; Lupus Erythematosus Systemic; Pemphigoid BullousMild proteinuriaArthritisDapsoneAntimalarials030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaPrednisoneimmune system diseasesPemphigoid BullousmedicineHumansChildskin and connective tissue diseases030203 arthritis & rheumatologyLupus erythematosusintegumentary systembusiness.industryMedicine (all)Dapsone; Lupus erythematosus systemic; Pemphigoid bullous; Medicine (all)ArticlesGeneral Medicinemedicine.diseasePemphigoid bullouDermatologyeye diseasesLupus erythematosus systemicFemaleBullous pemphigoidsense organsbusinessDapsonemedicine.drugPediatric population
researchProduct

New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?

2005

Interleukin-6 (IL-6) is a four-helical protein which, on target cells, binds to a specific IL-6-receptor and two molecules of the promiscuous signal transducing protein gp130. Structure-function analysis defined three molecular contact sites between IL-6 and its receptor subunits. Using this information, competitive antagonistic proteins as well as hyperagonistic proteins were developed. Possible therapeutic applications of IL-6 antagonists are in IL-6 dependent haematological disorders (Castleman's disease, POEMS syndrome, multiple myeloma) and bone diseases (Paget's disease, osteoporosis). Designer IL-6 antagonists could suppress inflammatory activity in rheumatic and autoimmune diseases …

PharmacologySystemic lupus erythematosusbiologybusiness.industryUnstable anginamedicine.medical_treatmentGlomerulonephritisGeneral Medicinemedicine.diseaseGlycoprotein 130CytokineImmunologymedicinebiology.proteinPharmacology (medical)businessInterleukin 6ReceptorMultiple myelomaExpert opinion on investigational drugs
researchProduct

Lipid presentation by the protein C receptor links coagulation with autoimmunity.

2021

A lipid-protein autoimmunity target Several autoimmune diseases, including systemic lupus erythematosus and primary antiphospholipid syndrome, are characterized by the presence of antiphospholipid antibodies (aPLs). These molecules can activate the complement and coagulation cascades, which contributes to pathologies such as thrombosis, stroke, and pregnancy complications. Müller-Calleja et al. found that endothelial protein C receptor (EPCR) in complex with lysobisphosphatidic acid (LBPA) is the cell-surface target for aPL and mediates its internalization (see the Perspective by Kaplan). aPL binding to EPCR-LBPA resulted in the activation of tissue factor–mediated coagulation and interfero…

Receptor complexAntigen presentationAutoimmunityEndosomesmedicine.disease_causeArticleAutoimmunityMiceInterferonimmune system diseasesmedicineAnimalsHumansLupus Erythematosus SystemicneoplasmsBlood CoagulationAutoantibodiesAutoimmune diseaseEndothelial protein C receptorAntigen PresentationMultidisciplinaryInnate immune systemLupus erythematosusEndothelial Protein C ReceptorThrombosismedicine.diseaseAntiphospholipid SyndromeImmunity InnateMice Mutant StrainsDisease Models AnimalSphingomyelin PhosphodiesteraseToll-Like Receptor 7ImmunologyAntibodies AntiphospholipidEmbryo LossMonoglyceridesEndothelium VascularLysophospholipidsmedicine.drugScience (New York, N.Y.)
researchProduct

Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling

2022

Abstract Background Autoimmune disorders, including Systemic Lupus Erythematosus (SLE), are associated with increased incidence of hematological malignancies. The matricellular protein osteopontin (OPN) has been linked to SLE pathogenesis, as SLE patients show increased serum levels of OPN and often polymorphisms in its gene. Although widely studied for its pro-tumorigenic role in different solid tumours, the role of OPN in autoimmunity-driven lymphomagenesis has not been investigated yet. Methods To test the role of OPN in the SLE-associated lymphomagenesis, the SLE-like prone Faslpr/lpr mutation was transferred onto an OPN-deficient background. Spleen from Faslpr/lpr and OPN-/-Faslpr/lpr …

STAT3 Transcription FactorMice Inbred MRL lprCancer ResearchLymphomaSettore MED/08 - Anatomia PatologicaAutoimmune DiseasesMice Inbred C57BLAutoimmunity Diffuse large B cell lymphoma OsteopontinMiceOncologyToll-Like Receptor 9Myeloid Differentiation Factor 88HumansAnimalsLupus Erythematosus SystemicSettore MED/05 - Patologia ClinicaMolecular MedicineSignal TransductionAdaptor Proteins Signal TransducingMolecular Cancer
researchProduct

[OP.3B.03] INFLUENCE OF SUBCLINICAL RENAL DAMAGE ON EARLY VASCULAR AGING IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

2016

Objective: It is well known that kidney is frequently involved in patients with Systemic Lupus Erythematosus (SLE) However, conflicting data exist about the impact of renal involvement on vascular damage in this group of patients. The aim of this study was to evaluate the influence of renal damage on assessed by aortic pulse wave velocity (aPWV), evaluated a by intima-media thickness (IMT) measurement and assessed by renal resistive index (RRI) measurement, in patients with SLE. Design and method: We enrolled 52 SLE subjects (mean age 39 +/- 12 years), divided in two subgroups according to ACR/SLICC classification: patients with lupus nephritis, (LNG), and individuals presenting other featu…

Settore MED/14 - NefrologiaPathologymedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyRenal damagebusiness.industrySystemic Lupus Erythematosus - Renal damage - Vascular damageSettore MED/16 - ReumatologiaInternal MedicinemedicineIn patientVascular agingCardiology and Cardiovascular MedicinebusinessSubclinical infectionJournal of Hypertension
researchProduct

Successful intravenous immunoglobulin treatment for steroid-resistant eosinophilic enteritis in a patient with systemic lupus erythematosus.

2011

Eosinophilic gastroenteritis is a rare condition of unknown etiology characterized by eosinophilic infiltration of the bowel. Corticosteroids are the mainstay of EG therapy. Although rare, steroid-resistant EG could be a life-threatening condition with tissue destructive evolution. Associations of eosinophilic gastroenteritis with systemic lupus erythematosus have rarely been reported. In this report we describe a case of successful IVIG treatment in a patient with systemic lupus erythematosus and steroid-refractory eosinophilic gastroenteritis. Eosinophilic gastroenteritis is a rare condition of unknown etiology characterized by eosinophilic infiltration of the bowel. Corticosteroids are t…

Settore MED/16 - ReumatologiaEosinophilic gastroenteritiimmune system diseasesEosinophilic gastroenteritis Sistemic Lupus Erythematosusrespiratory systemskin and connective tissue diseasesSistemic Lupus Erythematosus
researchProduct

Increased gingival blood vessel density in SLE patients

2012

Systemic lupus erythematosus (SLE) is a serious multisystem disease with a variety of cutaneous and oral manifestations. It is an autoimmune disorder whereby patients develop autoantibodies to many of their cells, cell components, and tissue. The microvascular changes in SLE play a role in the pathogenesis of this disease. The aim of this study was to investigate the gingival microcirculation in SLE patients. METHOD AND MATERIALs: Fifteen SLE patients and 15 healthy subjects were recruited for this study. Gingival microcirculation was investigated using videocapillaroscopy, a noninvasive technique that permits the in vivo evaluation of microvascular patterns. RESULTS: Significant difference…

Settore MED/28 - Malattie Odontostomatologichegingival vessels Systemic lupus erythematosus
researchProduct

Ādas izmaiņas pacientiem ar sistēmisku sarkano vilkēdi (SSV)

2018

Pētījuma nosaukums: Ādas izmaiņas pacientiem ar sistēmisku sarkano vilkēdi (SSV) Vispārēja informācija: Sistēmiska sarkanā vilkēde ir multifaktoriāla slimība ar plašu klīnisko izpausmju spektru. Ādas slimības ir svarīgs sarkanās vilkēdes klīniskais aspekts, jo āda ir otrs visbiežāk skartais orgāns pēc muskuļu un skeleta sistēmas. Saistībā ar to ādas izmaiņas var būt izšķirošas, lai agrīni atklātu sistēmisko slimību un to pienācīgi ārstētu.Mērķi. Galvenais pētījuma mērķi ir atrast, vai pastāv korelācija starp ādas izmaiņām, kuras var parādīties pacientiem ar sistēmisku sarkano vilkēdi un slimības aktivitāti. Un noteikt ādas bojājumus, kuriem ir saistība ar slimības aktivitāti. Materiāli un m…

Skin changesSLEDAIanti-dsDNASystemic Lupus erythematosusMedicīna
researchProduct

Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies.

2001

The induction of anti-DNA autoantibodies in systemic lupus erythematosus (SLE) patients is problematic because mammalian DNA is poorly immunogenic at best. Here we demonstrate a chain of connected antibodies in SLE patient sera that could account for the induction of anti-DNA antibody, and possibly for some of the pathogenic features of SLE. We now report that SLE patients, in addition to anti-DNA, produce antibodies to the carboxy-terminal domain of the tumour suppressor molecule p53; this p53 domain recognizes damaged DNA. Hence, these anti-p53 antibodies could mimic damaged DNA immunologically. Indeed, SLE sera do contain anti-idiotypic antibodies to a prototypic anti-p53 antibody. Moreo…

Systemic diseaseAnti-nuclear antibodyImmunologyBiologymedicine.disease_causeProtein Structure SecondaryAutoimmunityImmunoglobulin Idiotypesimmune system diseasesmedicineImmunology and AllergyHumansLupus Erythematosus Systemicskin and connective tissue diseasesAutoantibodiesAutoimmune diseaseLupus erythematosusMolecular MimicryAutoantibodymedicine.diseaseDNA-Binding ProteinsMolecular mimicryAntibodies AntinuclearImmunologyCancer researchbiology.proteinAntibodyTumor Suppressor Protein p53PeptidesJournal of autoimmunity
researchProduct

Autoreactivity to mouse C1q in a murine model of SLE.

1995

A large proportion of systemic lupus erythematosus (SLE) patients develop glomerulonephritis, coincident with the appearance of autoantibodies to C1q, the Fc-recognizing collagen-like subcomponent of the first component of complement, C1. The MRL/lpr/lpr mouse is an established model for SLE, developing both antinuclear and anti-type II collagen autoantibodies, and rheumatoid factors(s), exhibiting reduced complement levels and later on developing glomerulonephritis and often arthritis. We report here an age-dependent decrease in serum C1q levels coincident with the development of IgG2b autoantibodies reactive with mouse C1q in MRL/lpr/lpr mice. Unlike IgG2b, although high levels of IgM, Ig…

Systemic diseaseImmunologyArthritischemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesmedicine.disease_causeAutoimmunityMiceRheumatologyimmune system diseasesImmunology and AllergyMedicineAnimalsLupus Erythematosus Systemicskin and connective tissue diseasesAutoantibodiesLupus erythematosusbusiness.industryComplement C1qAutoantibodyGlomerulonephritismedicine.diseaseConnective tissue diseaseLupus NephritisDisease Models AnimalImmunologybusinessAnti-SSA/Ro autoantibodiesRheumatology international
researchProduct